Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Department of Medicine, Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Clin Transplant. 2023 Jun;37(6):e14960. doi: 10.1111/ctr.14960. Epub 2023 Mar 17.
Waitlist outcomes in liver transplantation (LT) for individual recipients are improved by use of allografts procured through donation after circulatory death (DCD). However, the impact of increased DCD acceptance on overall center outcomes is unknown.
Using the United Network for Organ Sharing database, 88 centers performing an average of ≥10 LTs/year between 1/2004 and 12/2019 were compared by percent DCD use quartile and categorized into four phenotypes according to temporal usage trends. Overall center median Model for End-stage Liver Disease at LT (MMaT), waitlist mortality, and waiting time were evaluated.
The overall DCD rate was 6.1% (N = 4906/80,709), ranging from 0% to 25.5%. Centers in the top DCD use quartile had lower MMaT (24 vs. 26; p < .001) and shorter overall waiting times (median 66 days vs. 90 days; p < .001) compared to bottom quartile centers. MMaT increased less over time at centers with increasing DCD use and was lower than at centers with declining DCD use (27 vs. 32; p = .017). Overall waitlist mortality between 2016 and 2019 was lower at increasing DCD use centers (17.8% vs. 22.5%, p = .034), yet did not affect 1-year mortality (p = .747).
The improved waitlist outcomes at centers with expanded DCD use extend beyond DCD recipients alone without negative consequences to overall post-LT center metrics.
在肝移植(LT)中,使用通过死后循环捐献(DCD)获得的同种异体移植物可改善个体受者的等待名单结果。然而,增加 DCD 接受率对整体中心结果的影响尚不清楚。
使用美国器官共享网络数据库,比较了 2004 年 1 月至 2019 年 12 月期间平均每年进行≥10 例 LT 的 88 个中心,按 DCD 使用量四分位数进行比较,并根据时间使用趋势分为四种表型。评估了整体中心中位模型终末期肝病(MMaT)、等待名单死亡率和等待时间。
总体 DCD 率为 6.1%(N=4906/80709),范围为 0%至 25.5%。DCD 使用量最高四分位数的中心 MMaT 较低(24 与 26;p<0.001),整体等待时间较短(中位数 66 天与 90 天;p<0.001)与四分位数最低的中心相比。随着 DCD 使用量的增加,中心的 MMaT 增加幅度较小,且低于 DCD 使用量减少的中心(27 与 32;p=0.017)。2016 年至 2019 年,DCD 使用量增加的中心整体等待名单死亡率较低(17.8%与 22.5%,p=0.034),但不影响 1 年死亡率(p=0.747)。
DCD 使用增加的中心等待名单结果的改善不仅限于 DCD 受者,而且对整体 LT 后中心指标没有负面影响。